|
|
|
| 
|
|
|
My Recent Searches
|
|
|
|
|
|
|
|
|
$0.00 0.00 (0.00%) as of 4:30 Fri 2/14
|
|
Download |
|
|
| |
| |
| Exchange: |
N/A |
| Security
Type: |
N/A |
| Shares
Out: |
48,230,000 |
| Market
Cap: |
N/A |
| Last
Volume: |
0 |
Avg
Vol: |
0 |
| 52
Week Range: |
$0 - $0 |
|
| Level
I Sector: |
N/A |
| Level
II Sector: |
N/A |
| Level
III Sector: |
N/A |
|
Member Indexes:
|
Rankings:
|
|
| Insider 3 Months : - |
| Insider 6 Months : - |
| Insider 3/6 Months : - |
|
| Guru Rank Number : - |
| Guru Rank Value : - |
| Guru Occurances : - |
|
|
|
|
|
| |
|
Company Profile Otonomy is a biopharmaceutical company focused on the development of innovative therapeutics for neurotology. Co. developed the application of drug delivery technology to the ear. Co.'s primary focus is on the development of three programs in its pipeline: OTO-313 in Phase 2 for tinnitus; OTO-413 in Phase 2a for hearing loss; and OTO-825, a gene therapy for congenital hearing loss, in investigational new drug (IND)-enabling activities. Additionally, Co. is conducting preclinical development of OTO-510 for otoprotection and OTO-6XX for severe hearing loss.
|
|
|
D/I:
|
|
|
D
is for direct shares.
I is
for indirect shares.
D/I
refers to the Direct or Indirect
shares traded vs. held. |
|
|
|
Forms:
|
|
|
A
Form 4 is a form filed
by an insider to indicate a change
in ownership.
A Form
3 is a form filed by
an insider to indicate an
initial ownership of a security. |
|
|
|
3m +/-:
|
|
|
|
This
represents the company's 3 month
price change. The initial price
is based on the closing price
of the stock on the day the transaction
took place. Purchases & sales
are viewed as long & short
positions respectively.
|
|
|
|
Actions:
|
|
|
| B |
Buy |
| S |
Sell |
| OE |
Option
Exercised |
| A |
Acquired |
| D |
Disposed |
| AB |
Automatic
Buy |
| AS |
Automatic
Sell |
| IO |
Initial
Ownership |
|
|
|
|
Download:
|
|
|
Download only Transactions
Forms. (Default)
Download
only Summary Infomation.
Download
both Transactions and Summary Data
|
|
|
|
|
| |
| |
Summary (Direct Transactions Only)  |
3 Months |
6 Months |
12 Months |
24 Months |
| Total Shares Bought |
0 |
0 |
0 |
0 |
| Total Buy Value |
$0 |
$0 |
$0 |
$0 |
| Total People Bought |
0 |
0 |
0 |
0 |
| Total Buy Transactions |
0 |
0 |
0 |
0 |
| Total Shares Sold |
0 |
0 |
0 |
42,242 |
| Total Sell Value |
$0 |
$0 |
$0 |
$4,342 |
| Total People Sold |
0 |
0 |
0 |
1 |
| Total Sell Transactions |
0 |
0 |
0 |
1 |
| End Date |
2024-01-28 |
2023-10-27 |
2023-04-28 |
2022-04-28 |
|
| Filer's Name |
Relation Title |
Off-Dir-10% |
Tran. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
| 3m +/- |
|
|
Form |
  Weber David Allen |
Director |
– • – |
2022-12-30 |
4 |
D |
$0.09 |
$8,064 |
D/D |
(91,636) |
285,863 |
|
- |
|
| Cayer Paul E |
President and CFBO |
• – – |
2022-12-28 |
4 |
D |
$0.09 |
$3,485 |
D/D |
(40,054) |
183,733 |
|
- |
|
| Capps Vickie L |
Director |
– • – |
2022-11-28 |
4 |
S |
$0.10 |
$4,342 |
D/D |
(42,242) |
3,400 |
|
- |
|
| Weber David Allen |
President & CEO |
• • – |
2022-03-28 |
4 |
S |
$2.41 |
$27,129 |
D/D |
(11,243) |
377,499 |
|
- |
|
| Savel Robert Michael Ii |
Chief Technical Officer |
• – – |
2022-03-28 |
4 |
S |
$2.41 |
$8,023 |
D/D |
(3,325) |
145,735 |
|
- |
|
| Cayer Paul E |
Ch. Financial & Business Offcr |
• – – |
2022-03-28 |
4 |
S |
$2.41 |
$13,571 |
D/D |
(5,624) |
223,787 |
|
- |
|
| Foster Alan Charles |
Chief Scientific Officer |
• – – |
2022-03-28 |
4 |
S |
$2.41 |
$6,175 |
D/D |
(2,559) |
177,017 |
|
- |
|
| Weber David Allen |
President & CEO |
• • – |
2022-03-25 |
4 |
S |
$2.39 |
$19,166 |
D/D |
(8,026) |
388,742 |
|
- |
|
| Savel Robert Michael Ii |
Chief Technical Officer |
• – – |
2022-03-25 |
4 |
S |
$2.39 |
$5,669 |
D/D |
(2,374) |
149,060 |
|
- |
|
| Cayer Paul E |
Ch. Financial & Business Offcr |
• – – |
2022-03-25 |
4 |
S |
$2.39 |
$9,588 |
D/D |
(4,015) |
229,411 |
|
- |
|
| Foster Alan Charles |
Chief Scientific Officer |
• – – |
2022-03-25 |
4 |
S |
$2.39 |
$4,363 |
D/D |
(1,827) |
179,576 |
|
- |
|
| Cayer Paul E |
Ch. Financial & Business Offcr |
• – – |
2022-01-14 |
4 |
A |
$0.00 |
$0 |
D/D |
100,000 |
233,426 |
|
- |
|
| Foster Alan Charles |
Chief Scientific Officer |
• – – |
2022-01-14 |
4 |
A |
$0.00 |
$0 |
D/D |
70,000 |
181,403 |
|
- |
|
| Weber David Allen |
President & CEO |
• • – |
2022-01-14 |
4 |
A |
$0.00 |
$0 |
D/D |
150,000 |
396,768 |
|
- |
|
| Savel Robert Michael Ii |
Chief Technical Officer |
• – – |
2022-01-14 |
4 |
A |
$0.00 |
$0 |
D/D |
70,000 |
151,434 |
|
- |
|
| Foster Alan Charles |
Chief Scientific OfficerOffice |
• – – |
2021-04-16 |
3 |
IO |
$0.00 |
$0 |
D/D |
0 |
51,403 |
|
- |
|
| Savel Robert Michael Ii |
Chief Technical Officer |
• – – |
2021-04-16 |
4 |
A |
$0.00 |
$0 |
D/D |
65,000 |
81,434 |
|
- |
|
| Cayer Paul E |
Ch. Financial & Business Offcr |
• – – |
2021-04-16 |
4 |
A |
$0.00 |
$0 |
D/D |
110,000 |
133,426 |
|
- |
|
| Weber David Allen |
President & CEO |
• • – |
2021-04-16 |
4 |
A |
$0.00 |
$0 |
D/D |
220,000 |
246,768 |
|
- |
|
| Lichter Jay |
Director |
– • – |
2021-03-03 |
4 |
S |
$2.70 |
$866,544 |
I/I |
(321,180) |
0 |
|
- |
|
| Lichter Jay |
Director |
– • – |
2021-03-02 |
4 |
S |
$2.90 |
$1,129,375 |
I/I |
(389,574) |
113,935 |
|
- |
|
| Lichter Jay |
Director |
– • – |
2021-03-01 |
4 |
S |
$2.86 |
$496,087 |
I/I |
(173,700) |
252,134 |
|
- |
|
| Lichter Jay |
Director |
– • – |
2021-02-26 |
4 |
S |
$2.83 |
$935,468 |
I/I |
(330,554) |
313,753 |
|
- |
|
| Lichter Jay |
Director |
– • – |
2021-02-25 |
4 |
S |
$2.95 |
$918,989 |
I/I |
(311,100) |
431,015 |
|
- |
|
| Lichter Jay |
Director |
– • – |
2021-02-24 |
4 |
S |
$2.98 |
$1,500,349 |
I/I |
(503,135) |
541,376 |
|
- |
|
131 Records found
|
|
Page 1 of 6 |
|
|
| |
Transaction Code Key: |
Ownership Code Key |
| |
B |
- Buy |
AB |
- Automatic Buy |
D |
- Direct Ownership |
| |
S |
- Sell |
AS |
- Automatic Sell |
I |
- Indirect Ownership |
| |
OE |
- Options Exercised |
A |
- Acquired |
| |
IO |
- Initital Ownership |
D |
- Disposed |
| |
|
|
|
|
|
